Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implant

Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. 

Corneal blindness is the third leading cause of blindness worldwide, affecting more than 13 million people. Corneal transplantation is the standard of care treatment, in which a patient’s damaged cornea is replaced by a human donor cornea. However, donor tissue shortages and surgical complexities limit can limit the availability of these procedures. 

“Pantheon Vision has assembled a world-leading ophthalmic design team whose groundbreaking mindset has enabled the bold development of a revolutionary single-piece polymer artificial cornea for vision restoration,” Mr. Guo Guangxu, founder and CEO of Eyedeal Medical, said in a recent press release. “This innovation, upon commercialization, will fundamentally eliminate the need for corneal donations while bringing new hope to global patients requiring corneal transplantation.”

This agreement is an important step in advancing Pantheon Vision’s mission to develop a bioengineered solution to restore vision, according to John Sheets, Jr., Ph.D., President and CEO. “We are grateful for the partnership with Eyedeal Medical and are extremely optimistic that together we can create an innovative solution that will provide meaningful benefits to patients suffering from corneal blindness,” he said. 

EyeDeal Medical stated they aim to expedite clinical implementation of the product to distribute worldwide as soon as possible.